Get the Stockscreener App
1.76
4.35%
-0.08
After Hours:
1.82
0.06
+3.41%
Marinus Pharmaceuticals Inc stock is traded at $1.76, with a volume of 443.97K.
It is down -4.35% in the last 24 hours and up +25.71% over the past month.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
See More
Previous Close:
$1.84
Open:
$1.82
24h Volume:
443.97K
Relative Volume:
0.66
Market Cap:
$97.50M
Revenue:
$30.99M
Net Income/Loss:
$-141.41M
P/E Ratio:
-11.73
EPS:
-0.15
Net Cash Flow:
$-118.12M
1W Performance:
+7.98%
1M Performance:
+25.71%
6M Performance:
-80.53%
1Y Performance:
-78.14%
1-Day Range:
$1.74
$1.88
1-Week Range:
$1.56
$1.97
52-Week Range:
$1.05
$11.26
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
Name
Marinus Pharmaceuticals Inc
Sector
Industry
Phone
484-801-4670
Address
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-23 | Initiated | RBC Capital Mkts | Outperform |
| Sep-30-20 | Initiated | Truist | Buy |
| Jul-01-20 | Initiated | Cowen | Outperform |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-09-20 | Initiated | Craig Hallum | Buy |
| Dec-20-19 | Initiated | Oppenheimer | Outperform |
| Mar-05-19 | Resumed | Jefferies | Buy |
| Feb-27-19 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-19 | Initiated | Leerink Partners | Outperform |
| Jul-02-18 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-20-18 | Initiated | Mizuho | Buy |
| Feb-15-18 | Initiated | H.C. Wainwright | Buy |
| Dec-14-17 | Initiated | Laidlaw | Buy |
| Aug-10-16 | Reiterated | Jefferies | Buy |
| Jun-14-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-08-16 | Reiterated | Stifel | Buy |
| Dec-17-15 | Initiated | RBC Capital Mkts | Outperform |
| Nov-17-15 | Initiated | Jefferies | Buy |
| Oct-30-15 | Reiterated | Oppenheimer | Outperform |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
View All
Marinus Pharmaceuticals Inc Stock (MRNS) Latest News
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy focus drives stock outlook - Investing.com
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Great week for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) institutional investors after losing 78% over the previous year - Yahoo Finance
Market Insight: Merus N.V (MRUS)’s Notable Drop, Closing at 47.77 - The Dwinnex
Marinus Pharmaceuticals (NASDAQ:MRNS) Rating Reiterated by Cantor Fitzgerald - MarketBeat
MinRex Resources Unveils Annual Financial Report - TipRanks
Marinus shares hold Buy rating on ganaxolone optimism By Investing.com - Investing.com Canada
Merus (NASDAQ:MRUS) Shares Sold by Integral Health Asset Management LLC - Defense World
Marinus Pharmaceuticals' (MRNS) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Marinus Pharmaceuticals to Outline Strategic Vision at Investor & Analyst Day - MSN
Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Upgraded by Oppenheimer - MarketBeat
Oppenheimer sees upside for Marinus Pharmaceuticals stock ahead of key trial results - Investing.com Canada
Oppenheimer sees upside for Marinus Pharmaceuticals stock ahead of key trial results - Investing.com Australia
Oppenheimer Upgrades Marinus Pharmaceuticals (MRNS) - MSN
Marinus nears key data readout for TSC seizure treatment - Investing.com
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day - BioSpace
Marinus Pharmaceuticals provides Ztalmy program update at investor day - TipRanks
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price - Simply Wall St
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day - StockTitan
Marinus Pharmaceuticals to Outline Strategic Vision at Investor & Analyst Day - MyChesCo
Marinus Pharmaceuticals (NASDAQ:MRNS) Rating Increased to Hold at StockNews.com - MarketBeat
Acadian Asset Management LLC Takes $813,000 Position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - MarketBeat
Marinus Pharmaceuticals to Present at 2024 Cantor Global Healthcare Conference - MyChesCo
Marinus Pharmaceuticals (NASDAQ:MRNS) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 - BioSpace
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 - Business Wire
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 - StockTitan
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference - Business Wire
Marinus Pharmaceuticals (NASDAQ:MRNS) Earns "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Upgraded by StockNews.com - MarketBeat
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $12.75 Average PT from Analysts - MarketBeat
Marinus Pharmaceuticals Inc (MRNS) may enjoy gains as insiders got busy in the recent days - Knox Daily
Marinus Pharmaceuticals Hosts Investor and Analyst Day - MyChesCo
Marinus Pharmaceuticals (NASDAQ:MRNS) Downgraded by StockNews.com to "Sell" - MarketBeat
Marinus Pharmaceuticals Reports Robust Q2 2024 Financial Results and Business Progress - MyChesCo
Cantor Fitzgerald Weighs in on Marinus Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:MRNS) - MarketBeat
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024 - StockTitan
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024 - Business Wire
LADENBURG THALM/SH SH Lowers Marinus Pharmaceuticals (NASDAQ:MRNS) to Neutral - Defense World
Marinus Pharmaceuticals (LTS:0JYL) Asset Turnover : 0.07 (As of Jun. 2024) - GuruFocus.com
Q3 2024 EPS Estimates for Marinus Pharmaceuticals, Inc. Reduced by HC Wainwright (NASDAQ:MRNS) - MarketBeat
Leerink Partnrs Brokers Cut Earnings Estimates for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Defense World
Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by HC Wainwright - Defense World
Marinus Pharmaceuticals, Inc. Expected to Post Q3 2024 Earnings of ($0.47) Per Share (NASDAQ:MRNS) - Defense World
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Simply Wall St
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
Thinking about buying stock in Archer Aviation, Marinus Pharmace - GuruFocus.com
Marinus Pharmaceuticals, Inc. Forecasted to Earn FY2028 Earnings of $2.72 Per Share (NASDAQ:MRNS) - MarketBeat
Marinus Pharmaceuticals, Inc. Forecasted to Earn FY2028 Earnings of $2.72 Per Share (NASDAQ:MRNS) - Defense World
Marinus Pharmaceuticals (NASDAQ:MRNS) Upgraded by StockNews.com to Hold - Defense World
Marinus Pharmaceuticals (NASDAQ:MRNS) Given "Buy" Rating at HC Wainwright - MarketBeat
Marinus Pharmaceuticals Inc Stock (MRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):